Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Non-Current Debt (2024 - 2025)

Pelthos Therapeutics has reported Non-Current Debt over the past 2 years, most recently at $131868.0 for Q2 2025.

  • Quarterly results put Non-Current Debt at $131868.0 for Q2 2025, changed 0.0% from a year ago — trailing twelve months through Jun 2025 was $131868.0 (changed 0.0% YoY), and the annual figure for FY2024 was $132000.0, changed.
  • Non-Current Debt for Q2 2025 was $131868.0 at Pelthos Therapeutics, roughly flat from $131868.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for PTHS hit a ceiling of $132000.0 in Q4 2024 and a floor of $131868.0 in Q2 2024.